<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04455906</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00035467</org_study_id>
    <nct_id>NCT04455906</nct_id>
  </id_info>
  <brief_title>Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism</brief_title>
  <official_title>Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with
      increased clinical, immunological and microbial markers of disease activity in patients with
      AD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this participants between the ages of 6-65 who have atopic dermatitis and don't have any
      of the exclusion criteria will be invited to participate in the study. There will be a 1 time
      visit where questionnaires, blood draw, skin swab and skin biopsies will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>atopic dermatitis severity</measure>
    <time_frame>baseline, only 1 time point</time_frame>
    <description>validated assessment EASI score</description>
  </primary_outcome>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Atopic Dermatitis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, skin tape, biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        atopic dermatitis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female participants ≥6 to 65 yrs of age

          2. Meet AD Standard Diagnostic Criteria

        Exclusion Criteria:

          1. Enrollment in another clinical trial

          2. Hypersensitivity to an agent used for the skin decolonization protocol

          3. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs
             (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine,
             methotrexate)

          4. Phototherapy for AD within 4 weeks

          5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen
             weeks

          6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days

          7. Bleach baths within 7 days of the first Visit

          8. Use of oral or topical antibiotics within 21 days of the beginning of the study

          9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids

         10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy

         11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell
             lymphoma,,

         12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune
             disease.

         13. Febrile illness at time of visits

         14. Suspected immune deficiency or family history of primary immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Amparita Cunnignham</last_name>
    <phone>857-218-5336</phone>
    <email>asthma@childrens.harvad.edu</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Wanda Phipatanakul</investigator_full_name>
    <investigator_title>Professor of Pediatrics, Director Asthma Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

